List of Excipients in Branded Drug CYPROHEPTADINE HYDROCHLORIDE SOLUTION

Generic Drugs Containing CYPROHEPTADINE HYDROCHLORIDE SOLUTION

Company	Ingredient	NDC	Excipient
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	ALCOHOL
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	ANHYDROUS CITRIC ACID
Method Pharmaceuticals LLC	cyproheptadine hydrochloride	58657-697	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in CYPROHEPTADINE HYDROCHLORIDE SOLUTION?

# Of NDCs	Excipient
1	ALCOHOL
1	ANHYDROUS CITRIC ACID
1	D&C YELLOW NO. 10

Cyproheptadine Hydrochloride Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 25, 2026

Cyproheptadine hydrochloride solution is a mature, low-barrier generic product with limited composition-of-matter or formulation patent protection. Commercial differentiation is more likely to come from excipient selection, pediatric usability, preservative strategy, manufacturing reliability, packaging, and distribution than from exclusivity. The strongest opportunities are sugar-free, alcohol-free, low-allergen, unit-dose, and better-palatable oral solutions supported by stability and human-factors data.

What is cyproheptadine hydrochloride solution?

Cyproheptadine hydrochloride is an oral first-generation antihistamine with antiserotonergic activity. U.S. labeling identifies the product for perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, and acute manifestations of urticaria and angioedema. The drug is also used off label as an appetite stimulant, although appetite stimulation is not the principal FDA-approved indication.[1]

The conventional oral liquid strength is 2 mg per 5 mL, equivalent to 0.4 mg/mL. Products are generally marketed as syrup or oral solution, depending on the formulation and regulatory filing.

Attribute	Commercial relevance
Active ingredient	Cyproheptadine hydrochloride
Common liquid strength	2 mg/5 mL
Route	Oral
Primary approved uses	Allergic rhinitis, urticaria, angioedema and related allergic conditions
Pharmacologic class	First-generation H1 antihistamine with antiserotonergic activity
Common users	Pediatric and adult patients
Key risks	Sedation, anticholinergic effects, paradoxical excitation, dosing errors
Regulatory category	Small-molecule prescription product in the United States
Biosimilar exposure	None
Main competitive threat	Generic oral solids and generic oral liquids

The product is commercially sensitive to taste, dosing convenience, sugar content, preservative tolerability, and pharmacy substitution.

What patents protect cyproheptadine hydrochloride solution?

No meaningful active U.S. composition-of-matter patent estate protects cyproheptadine hydrochloride. The active ingredient was developed decades ago, and the core drug patent term has expired.

The relevant commercial protection is therefore based on regulatory approval, manufacturing capability, trademarks, customer contracts, and potential formulation know-how rather than exclusivity over the molecule.

Protection category	Current position
Composition-of-matter patent	Expired
Core therapeutic-use patent	Expired or commercially irrelevant
Conventional 2 mg/5 mL liquid formulation patent	No material blocking estate identified
Orange Book patent protection	No significant active patent barrier expected for the conventional product
FDA exclusivity	Expired for the historical reference product
Trade secret opportunity	Stability, flavor system, preservative package, process controls and packaging
Trademark opportunity	Product name, device presentation and brand positioning

A sponsor should verify the current FDA Orange Book entry, reference listed drug designation, patent certifications, and any later-added listings before filing or launching. The Orange Book determines whether an approved reference product has listed patents or exclusivity that affect an abbreviated new drug application.[2]

When does cyproheptadine hydrochloride solution lose exclusivity?

Cyproheptadine hydrochloride lost practical market exclusivity many years ago. The product is a mature generic opportunity rather than a near-term loss-of-exclusivity product.

The original Periactin product was marketed by Merck. Current U.S. products are supplied by generic manufacturers and distributors under cyproheptadine hydrochloride syrup or oral-solution labels. FDA approval of multiple generic liquid products indicates that the basic formulation is open to competition.

Exclusivity timeline

Milestone	Status
Original small-molecule development	Historical
Original patent protection	Expired
Reference product commercialization	Historical
Generic tablet and liquid approvals	Established
Current FDA exclusivity	No material exclusivity expected
Current launch barrier	Formulation execution, bioequivalence or pharmaceutical equivalence, manufacturing and distribution

Because there is no significant remaining exclusivity, a new entrant does not need to wait for a major patent expiration. The commercial question is whether the entrant can obtain approval at an acceptable cost and capture a defensible channel.

What is the FDA regulatory status of cyproheptadine oral solution?

Cyproheptadine hydrochloride oral liquid is regulated as a conventional prescription drug. A manufacturer can generally pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence, where applicable, to the reference listed drug.

A 505(b)(2) application may be relevant when the proposed product differs materially from the reference product in concentration, excipient system, dosage form, delivery device, or other clinically relevant attribute. A 505(b)(2) strategy may support a differentiated product but normally carries greater development and regulatory cost than an ANDA.

Likely regulatory routes

Product concept	Potential pathway
Same active ingredient, strength, dosage form and route	ANDA
Same strength with different inactive ingredients	Often ANDA if requirements are met
New concentration or materially different delivery profile	ANDA or 505(b)(2), depending on FDA determination
Pediatric unit-dose presentation	ANDA if pharmaceutically equivalent; otherwise possible 505(b)(2)
Novel excipient or clinically meaningful formulation change	505(b)(2) risk increases
Compounded pharmacy preparation	Not a commercial FDA-approved product

FDA review will focus on identity, strength, quality, purity, potency, microbiological quality, container-closure integrity, preservative effectiveness where applicable, and labeling. For oral liquids, analytical and stability controls are central because concentration uniformity and microbial contamination can affect patient safety.[3]

What excipients are used in cyproheptadine hydrochloride solution?

The excipient system must maintain drug solubility, chemical stability, microbial control, acceptable taste, and dose uniformity. Public labels for cyproheptadine oral liquids vary by manufacturer, so the formulation should be assessed product by product rather than inferred from the active ingredient.

Typical excipient classes include:

Excipient function	Candidate materials	Development issue
Vehicle	Purified water	Microbial control and packaging compatibility
Sweetener	Sucrose, sorbitol, sucralose, other high-intensity sweeteners	Dental risk, glycemic burden, gastrointestinal tolerance
Humectant	Glycerin, propylene glycol, sorbitol	Mouthfeel, viscosity and pediatric acceptability
Preservative	Sodium benzoate, parabens or other approved systems	Age-specific safety, pH dependence and preservative effectiveness
Buffer or pH adjuster	Citric acid, citrate salts, phosphate systems	Solubility, taste, preservative performance and stability
Flavor	Fruit, berry, citrus or masking flavors	Bitterness, flavor carryover and allergen labeling
Colorant	Approved color additives or no colorant	Pediatric perception and regulatory preference
Viscosity modifier	Cellulose derivatives, xanthan gum or similar agents	Pourability, dose recovery and syringe accuracy
Chelator	Disodium EDTA where justified	Metal-ion control and preservative support
Antioxidant	Product-specific antioxidant system	Must be justified by degradation pathways

The exact formulation should be established through forced-degradation studies, pH-solubility work, preservative effectiveness testing, accelerated stability, long-term stability, extractables and leachables testing, and dosing-device studies.

Which excipient strategies create the strongest commercial opportunity?

Sugar-free and low-glycemic formulations

A sugar-free product can address parents, pediatric practices, dental-conscious consumers, and patients with diabetes or dietary restrictions. Sorbitol, glycerin, and high-intensity sweeteners can replace sucrose, but excessive polyol content can cause gastrointestinal discomfort.

The commercial value depends on more than removing sucrose. The formulation must retain acceptable taste, maintain viscosity, and deliver consistent doses through an oral syringe. A sugar-free claim should be supported by quantitative composition and compliant labeling.

Alcohol-free formulations

An alcohol-free product may be commercially attractive for pediatric use and institutional formularies. Alcohol content can affect acceptability, caregiver concerns, and procurement policies. A sponsor should avoid relying on alcohol as a primary solubilizer unless it is necessary and clinically justified.

Preservative-minimized or preservative-free presentations

A multidose aqueous oral solution generally requires microbial-control measures. A preservative-free product is more technically difficult and may require unit-dose packaging, sterile manufacture, shorter in-use dating, or a validated antimicrobial container system.

The most practical strategy is often a unit-dose cup, stick pack, or single-use syringe. This shifts cost from formulation complexity to packaging and logistics but can create differentiation in hospitals, pediatric clinics, and specialty pharmacies.

Improved taste and bitterness masking

Cyproheptadine has a bitter pharmaceutical taste. Flavor-only masking may be inadequate. A stronger approach combines sweetener balance, pH control, viscosity adjustment, flavor selection, and taste-masking excipients compatible with aqueous systems.

Taste testing should include children or an appropriately representative pediatric proxy population where permitted. A palatability advantage can improve adherence but is difficult to protect with a patent unless supported by a specific, non-obvious formulation.

Device-led dosing accuracy

An oral syringe can reduce dosing errors compared with a household teaspoon. The product opportunity is strongest where the package includes a clearly graduated device, an adapter, child-resistant closure, and instructions that match the marketed concentration.

Concentration changes create medication-error risk. A higher-concentration product may reduce administration volume but can increase the consequences of a measuring error. A sponsor should treat concentration, label design, syringe graduation, and caregiver comprehension as one product system.

What formulations are protected or protectable?

The conventional 2 mg/5 mL syrup or solution is unlikely to support strong patent protection. Patentability improves when a formulation solves a defined technical problem with reproducible data.

Potentially protectable concepts include:

1. A specific excipient ratio that improves long-term chemical stability.
2. A preservative-free unit-dose aqueous formulation with defined microbial limits and in-use performance.
3. A taste-masked composition with a demonstrated reduction in bitterness.
4. A low-volume, higher-concentration formulation with acceptable safety and dose accuracy.
5. A suspension or multiparticulate system if solubility or controlled administration creates a real technical advantage.
6. A container-closure system that limits oxygen, light, moisture or microbial ingress.
7. A formulation with improved compatibility with enteral feeding tubes.
8. A manufacturing process that reduces degradation or improves content uniformity.

The patent should claim the formulation through objective parameters such as pH, concentration ranges, excipient ratios, impurity thresholds, preservative content, viscosity, particle size where relevant, or stability after defined storage conditions. Generic claims covering "a pharmaceutically acceptable excipient" would have limited defensive value.

How many patents cover cyproheptadine hydrochloride solution?

For the conventional product, the meaningful number of blocking patents is expected to be zero or close to zero in the United States. The commercial patent opportunity lies in new formulation claims, packaging claims, manufacturing claims, or drug-device combinations.

A freedom-to-operate review should separate:

• Expired cyproheptadine compound patents.
• Expired historical use patents.
• Active third-party excipient or delivery-system patents.
• Patents covering preservative systems.
• Patents covering pediatric dosing devices.
• Patents covering unit-dose packaging.
• Patent applications filed for improved taste or stability.

A new entrant should not assume that an old active ingredient creates freedom to operate across every excipient or device. A particular packaging system, flavor technology, or preservative combination can remain protected even when the active ingredient is not.

Are there Paragraph IV challenges for cyproheptadine hydrochloride solution?

Paragraph IV litigation is unlikely to be a major issue for the conventional cyproheptadine liquid market because the core product is old and generic competition is established. A Paragraph IV certification becomes relevant only if an ANDA applicant references a listed drug with an unexpired Orange Book patent.

The expected certification landscape is:

Issue	Assessment
Core cyproheptadine patent	No practical barrier expected
Conventional liquid formulation patent	No material barrier expected
Method-of-use patent	Unlikely to block ordinary generic labeling if expired or carved out
Device patent	Relevant only to a specific packaged presentation
Paragraph IV litigation	Low probability for the basic product
Patent litigation risk	More likely for a differentiated formulation than for the molecule

A sponsor should evaluate skinny-label options if any listed method-of-use patent remains relevant. The labeling must avoid patented uses while preserving the commercial indication set permitted under the ANDA.

What method-of-use patents affect cyproheptadine?

Historical medical-use patents covering antihistamine or antiserotonergic applications are unlikely to create meaningful present-day exclusivity. Off-label appetite stimulation is a commercial use area but does not automatically create a proprietary indication.

A sponsor should avoid promotional claims for appetite stimulation unless supported by an approved label or a separately developed regulatory strategy. Off-label market demand can influence prescribing, but it does not provide a reliable patent moat and can increase promotional and compliance risk.

Which companies are challenging or competing with cyproheptadine products?

Competition is fragmented among generic pharmaceutical manufacturers, contract manufacturers, wholesalers, pharmacies, and compounding pharmacies. The product can compete against:

• Generic cyproheptadine tablets.
• Generic cyproheptadine syrup or oral solution.
• Other antihistamines with less sedation.
• Clinician-selected appetite-stimulation therapies.
• Compounded oral liquids for patients unable to swallow tablets.

The principal commercial competitors are not necessarily other cyproheptadine manufacturers. Non-sedating antihistamines, including cetirizine, loratadine, and fexofenadine, compete for allergic rhinitis and urticaria prescriptions. These products may have stronger modern brand recognition and lower sedation concerns.

Cyproheptadine retains a liquid-dosage-form advantage for patients who cannot swallow tablets. That advantage is strongest in pediatrics, selected neurologic or feeding-related uses, and institutional settings.

How does cyproheptadine solution compare with competing oral liquids?

Product characteristic	Cyproheptadine solution	Modern second-generation antihistamine liquid
Sedation	Higher risk	Generally lower
Pediatric liquid availability	Established	Established
Generic competition	High	High
Appetite-stimulation use	Common off label	Limited or not typical
Anticholinergic burden	Material	Generally lower
Formulation differentiation	Primarily excipient and device based	Similar
Price pressure	High	High
Clinical differentiation	Liquid access and antiserotonergic activity	Better tolerability for allergy treatment

A commercial product should not compete solely on price. A sugar-free, alcohol-free, better-tasting product with a calibrated syringe and reliable supply can command preferred status with selected distributors even in a low-price generic category.

What generic launch risks exist for cyproheptadine hydrochloride solution?

The primary launch risks are technical and operational rather than patent-related.

Formulation risks

• Precipitation or loss of assay during storage.
• Preservative failure at the selected pH.
• Flavor degradation or color change.
• Dose nonuniformity after shaking or storage.
• Interaction with oral syringes, adapters or enteral tubes.
• Excessive viscosity that impairs dose withdrawal.
• Inadequate microbial control after opening.

Regulatory risks

• Failure to match the reference product's dosage form or strength.
• Inactive-ingredient differences requiring additional justification.
• Inadequate bioequivalence strategy.
• Labeling that creates concentration confusion.
• Incomplete pediatric-use data for a differentiated formulation.
• Failure to demonstrate container-closure integrity.

Commercial risks

• Wholesale price erosion.
• Limited pharmacy shelf space.
• Low prescription volume relative to manufacturing complexity.
• Substitution by tablets or alternative antihistamines.
• Product shortages caused by a small supplier base.
• High packaging cost for preservative-free or unit-dose products.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are manageable but can determine profitability. Aqueous oral liquids require validated compounding, homogeneity controls, microbial monitoring, filling accuracy, and suitable cleaning procedures. Preservative-containing products still require evidence that the preservative system remains effective throughout shelf life and in-use conditions.

The most defensible manufacturing know-how may include:

• Order of addition for excipients.
• pH adjustment sequence.
• Temperature control during dissolution.
• Mixing parameters.
• Deaeration and oxygen control.
• Filtration or clarification.
• Filling-line controls.
• Compatibility between formulation and closure.
• Cleaning validation for sticky sweetener systems.

Process patents may be less valuable than trade secrets if the process is difficult to detect from the finished product. Formulation patents become more useful when the product has measurable advantages over existing liquids.

What is the revenue exposure and commercial opportunity?

Public company filings generally do not isolate cyproheptadine hydrochloride solution revenue. The product is typically included within broader generic prescription portfolios. Revenue should therefore be modeled from prescription volume, net price, market share, channel mix, and supply reliability rather than from historic branded sales.

A practical commercial model is:

Revenue driver	Effect
High prescription volume	Supports scale but increases price competition
Low number of liquid competitors	Improves supply leverage
Pediatric demand	Favors palatability and dosing-device differentiation
Institutional contracts	Favors unit-dose and preservative-control formats
Sugar-free positioning	Expands formulary and caregiver appeal
Concentrated presentation	Reduces shipping volume but increases dosing risk
Reliable supply	Can support wholesaler and pharmacy retention
Tablet substitution	Limits long-term liquid growth

The best opportunity is a focused specialty-generic strategy rather than a broad mass-market launch. A sponsor with pediatric distribution, hospital access, or an existing oral-liquid manufacturing platform can obtain more value than a sponsor competing only on wholesale acquisition cost.

What licensing deals are relevant to cyproheptadine solution?

No major current licensing transaction is required to commercialize the conventional active ingredient. Licensing may be useful for:

• Taste-masking technology.
• Preservative-free multidose packaging.
• Oral-syringe or bottle-adapter systems.
• Pediatric formulation platforms.
• Contract manufacturing capacity.
• Regional distribution rights.
• Existing approved product rights.

A license should be evaluated against the low intrinsic value of an old generic molecule. Royalty-bearing technology is justified only if it improves approval probability, reduces manufacturing cost, prevents a supply problem, or creates a differentiated claim supported by market access.

What is the geographic coverage of cyproheptadine solution?

Cyproheptadine is marketed in multiple countries, but product names, strengths, prescription status, excipient requirements, and approved indications vary. A U.S. formulation cannot automatically be commercialized internationally without country-specific review.

Key geographic issues include:

• Maximum permitted preservative levels.
• Pediatric excipient restrictions.
• Sugar and alcohol labeling.
• Approved colorants and flavors.
• Medical-device requirements for dosing syringes.
• Local reference products.
• National reimbursement and substitution rules.
• Stability zones and packaging requirements.

A regional strategy should prioritize markets where oral liquids are routinely prescribed and where pediatric supply is limited. Local manufacturing or a qualified contract manufacturer may improve procurement access in markets with import constraints.

How strong is the patent estate for cyproheptadine hydrochloride solution?

The patent estate is weak for the conventional solution and potentially moderate for a technically differentiated product.

Patent strategy	Relative strength
Cyproheptadine compound patent	None commercially
Conventional syrup composition	Weak
Generic flavor claim	Weak
Defined taste-masking system with comparative data	Moderate
Preservative-free unit-dose system	Moderate
Novel concentration with validated dosing advantage	Moderate, subject to prior art
Container-closure combination	Moderate
Manufacturing process with detectable product signature	Moderate
Brand and supply reliability	Commercial rather than patent strength

The most realistic IP plan combines a narrow formulation patent, trade secrets covering process parameters, and a branded package that improves pediatric administration.

Key Takeaways

• Cyproheptadine hydrochloride solution is a mature generic product with no meaningful core patent barrier.
• The conventional 2 mg/5 mL liquid is unlikely to support strong exclusivity.
• Sugar-free, alcohol-free, better-tasting, preservative-minimized, and unit-dose products offer the clearest commercial differentiation.
• Pediatric dosing devices and concentration control are central to product safety and market acceptance.
• An ANDA is the likely route for a pharmaceutically equivalent product; a 505(b)(2) application may apply to a materially differentiated formulation.
• Paragraph IV and biosimilar risks are low for the conventional product.
• The principal business risks are price erosion, manufacturing complexity, microbial stability, palatability, and tablet substitution.
• A focused specialty-generic strategy is more attractive than an undifferentiated price launch.
• The strongest protectable assets are defined formulation combinations, packaging systems, manufacturing know-how, and trade secrets.

FAQs

Is cyproheptadine hydrochloride solution available without sugar?

Some commercial products may use sucrose-free or alternative sweetener systems, but the inactive ingredients must be confirmed from the specific product label. A sugar-free formulation is a viable product-development opportunity.

Can cyproheptadine oral solution be marketed as an appetite stimulant?

Appetite stimulation is a recognized off-label use but is not the principal FDA-approved indication in conventional cyproheptadine labeling. Commercial labeling and promotion must remain within the approved regulatory framework.

Is cyproheptadine hydrochloride solution suitable for compounded pharmacy use?

Pharmacies may compound oral liquids for patients who cannot use marketed dosage forms, subject to applicable federal and state requirements. A compounded preparation is distinct from an FDA-approved commercial product.

Does a higher concentration create a patent opportunity?

A higher concentration can support patent claims only if it provides a non-obvious technical or clinical advantage, such as improved stability, lower administration volume, or validated dosing performance. Concentration alone is unlikely to create strong protection.

What packaging is most attractive for a pediatric cyproheptadine product?

A bottle with a calibrated oral syringe, child-resistant closure, tamper evidence, and clear concentration labeling is the most practical baseline. Unit-dose packaging may offer additional value for hospitals and preservative-minimized formulations.

References

1. U.S. Food and Drug Administration. (2023). Cyproheptadine hydrochloride syrup: Prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (1997). Guidance for industry: SUPAC-IR: Immediate-release solid oral dosage forms. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2014). Guidance for industry: Inactive ingredient database. U.S. Department of Health and Human Services.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.